Adefovir Dipivoxil in the Treatment of Chronic Hepatitis B

Annals of Pharmacotherapy

Volumn 38, Issue 4, 2004, Pages 625-633

  Rivkin, Anastasia M ^a,b  

^a LONG ISLAND UNIVERSITY   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; Nucleotide analog

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA2B INTERFERON; COTRIMOXAZOLE; HEPATITIS E ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PARACETAMOL; VIRUS DNA;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIVIRAL ACTIVITY; ASTHENIA; BACKACHE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG SCREENING; DYSPEPSIA; FLATULENCE; FLU LIKE SYNDROME; HEADACHE; HEPATITIS B; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIVER DYSFUNCTION; META ANALYSIS; NAUSEA; NEPHROTOXICITY; PAIN; PHARYNGITIS; PHOSPHATE BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STEATOSIS; TERATOGENICITY; TREATMENT OUTCOME; VIRUS CARRIER;

ADENINE; ANTIVIRAL AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LIVER TRANSPLANTATION; PHOSPHONIC ACIDS; RANDOMIZED CONTROLLED TRIALS;

EID: 1542429643     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D362     Document Type: Review

References (56)

1. Lok AS. Chronic hepatitis B. N Engl J Med 2002;346:1682-3.
2. Rivkina A, Rybalov S. Chronic hepatitis B: current and future treatment options. Pharmacotherapy 2002;22:721-37.
3. Veenstra D, Sullivan S, Iloeje U. Estimation of future hepatitis B disease burden in the United States using a disease simulation model (abstract). Hepatology 2002;36:615A.
4. Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 2003;23:81-8.
5. Alexander GJ, Brahm J, Fagan EA, Smith HM, Daniels HM, Eddleston AL, et al. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987;2:66-9.
6. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988;95:1318-25.
7. Brook MG, Chan G, Yap I, Karayiannis P, Lever AM, Jacyna M, et al. Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. BMJ 1989;299:652-6.
8. Saracco G, Mazzella G, Rosina F, Cancellieri C, Lattore V, Raise E, et al. A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology 1989;10:336-41.
9. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
10. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121:101-9.
11. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
12. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
13. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999;29:889-96.
14. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51.
15. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999;36:127-43.
16. FDA approves new treatment for chronic hepatitis B. FDA Talk Paper, Rockville, MD: Food and Drug Administration, September 20, 2002.
17. Zoulim F. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance. Semin Liver Dis 2002;22(suppl 1):23-31.
18. Kearney B, Knight W, Curry G, Beutelspacher D, Ebrahimi R, Gill S, et al. Adefovir dipivoxil pharmacokinetics in subjects with chronic hepatitis B and in healthy subjects (abstract). Presented at: European Association for the Study of the Liver. Madrid, April 15-21, 2002:306A.
19. Prescribing information. Hepsera (adefovir dipivoxil). Foster City, CA: Gilead Sciences, September 2002.
20. Balzarini J, Hao Z, Herdewijn P, Johns DG, De Clercq E. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci U S A 1991;88:1499-503.
21. Heathcote EJ, Jeffers L, Wright T, Sherman M, Perrillo R, Sacks S, et al. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo controlled Phase II studies (abstract). Hepatology 1998;28:317A.
22. Heathcote EJ, Jeffers L, Perrillo R, Wright T, Sherman M, Namini H, et al. Sustained antiviral response and lack of viral resistance with long term adefovir dipivoxil (ADV) therapy in chronic HBV infection (abstract). Presented at: 37th Annual Meeting of the European Association for the Study of the Liver. Madrid, April 15-21, 2002:590A.
23. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
24. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7.
25. Shaw T, Bowden S, Locarnini S. Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints. Gastroenterology 2002;123:2135-40.
26. Marcellin P, Chang TT, Lim SG, Sievert W, Tong MJ, Jain A, et al. Adefovir dipivoxil (ADV) 10 mg for the treatment of patients with HBeAg+ chronic hepatitis B: continued efficacy beyond 48 weeks (abstract). Presented at: 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, 2002:101411A.
27. Hadziyannis SJ, Tassopoulos NC, Heathcote J, Chang TT, Kitis G, Rizzetto M, et al. Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B. Presented at: 38th European Association for the Study of the Liver. Istanbul, March 28-April 1, 2003.
28. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-96.
29. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-6.
30. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-34.
31. Zoulim F, Trepo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol 1998;29:151-68.
32. Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β -L-arabinofuranosyluracil. Antimicrob Agents Chemother 2001;45:2495-501.
33. Ono-Nita SK, Kato N, Shiratori Y, Lan KH, Yoshida H, Carrilho FJ, et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999;103:1635-40.
34. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998;28:1669-73.
35. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34.
36. Peters M, Hann HW, Martin P, Heathcote EJ, Buggisch P, Moorat A, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis (abstract). Hepatology 2002;36:374A.
37. Schiff E, Willems B, Leung NW, Lau G, Trepo C, Wright T, et al. Addition of adefovir dipivoxil to lamivudine therapy results in significant reduction in HBV DNA and serum ALT in compensated chronic hepatitis B patients with YMDD variant HBV and a reduced response to lamivudine - 52 week results (abstract). Hepatology 2002;36:636A.
38. Perrillo R, Schiff E, Hann HW, Buti M, Strasser S, Watkins K, et al. The addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis B patients with YMDD variant HBV and reduced response to lamivudine - preliminary 24 week results (abstract). Hepatology 2001;34:349A.
39. Mutimer D, Hann HW, Buti M, Strasser S, Watkins K, Woessner M, et al. Significant clinical improvement following the addition of adefovir dipivoxil to lamivudine in decompensated patients with YMDD variant HBV and reduced response to lamivudine - 1 year results (abstract). Hepatology 2002;36:625A.
40. Sung J, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo R, et al. A randomised double blind Phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment-naïve patients with chronic hepatitis B (oral presentation). Presented at: 38th European Association for the Study of the Liver. Istanbul, March 28-April 1, 2003.
41. Walsh KM, Woodall T, Lamy P, Wight DG, Bloor S, Alexander GJ. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001;49:436-40.
42. Mutimer D, Feraz-Neto BH, Harrison R, O'Donnell K, Shaw J, Cane P, et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001;49:860-3.
43. Foxton M, Maulayah P, Lama N, Norris S. Efficacy and safety of adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B pre- and post-liver transplantation (abstract). Hepatology 2002;36:658A.
44. Schiff E, Lai CL, Neuhaus P. Adefovir dipivoxil (ADV) for the treatment of chronic hepatitis B patients pre- and post-liver transplantation (OLT) with lamivudine-resistant (LAM-R) hepatitis B virus (HBV) patients (abstract). Presented at: 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 1-5, 2002.
45. Westland C, Gibbs CS, Miller M, Lama N, Fry J, Brosgart CL, et al. Resistance monitoring in patients with lamivudine-resistant HBV post liver transplantation who received adefovir therapy for 1 year (abstract). Hepatology 2002;36:644A.
46. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-7.
47. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-23.
48. Benhamou Y, Thibault V, Calvez V, Fievet MH, Pitie-Salpetriere G. 96 week efficacy and safety of adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in chronic hepatitis B patients co-infected with HIV (abstract). Hepatology 2002;36:638A.
49. Thibault V, Benhamou Y, Bochet M, Mousnier F, Sullivan M, Brosgart C. 96 weeks of adefovir dipivoxil (ADV) therapy in chronic hepatitis B patients coinfected with HIV and lamivudine-resistant (LAM-R) HBV is not associated with emergence of specific HBV polymerase mutations (abstract). Hepatology 2002;36:639A.
50. Delaugerre C, Marcelin AG, Thibault V, Peytavin G, Bombled T, Bochet MV, et al. Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 2002;46:1586-8.
51. Skowron G, Kuritzkes DR, Thompson MA, Squires KE, Goodwin SD, Dusak BA, et al. Once-daily quadruple-drug therapy with adefovir dipivoxil, lamivudine, didanosine, and efavirenz in treatment-naïve human immunodeficiency virus type 1-infected patients. J Infect Dis 2002;186:1028-33.
52. Chang T. Long term safety of adefovir dipivoxil (ADV) 10 mg once daily for chronic hepatitis B (CHB): an integrated analysis of two Phase 3 studies. Presented at: 38th European Association of the Study of the Liver. Istanbul, March 28-April 1, 2003.
53. Kearney B, Knight W, Curry G, Contreras J, Wolf J, Gill S, et al. A drug-drug interaction study between adefovir dipivoxil and lamivudine, acetaminophen, ibuprofen, and trimethoprim/sulfamethoxazole (abstract). Presented at: Annual Meeting of the European Association for the Study of the Liver, Madrid, April 15-21, 2002:606A.
54. Knight W, Hayashi S, Benhamou Y, Curry G, Ebrahimi R, Gill S, et al. Dosing guidelines for adefovir dipivoxil in the treatment of chronic hepatitis B patients with renal or hepatic impairment (abstract). The European Association for the Study of the Liver. Madrid, 2002:308A.
55. Drug topics red book, 2003: Montvale, NJ: Medical Economics.
56. Kearney B, Curry G, Knight W, Jain A, Ebrahimi R, Pol S, et al. Development and evaluation of dosing guidelines for adefovir dipivoxil in patients with chronic hepatitis B and renal impairment (abstract). Hepatology 2002;36:638A.